Is Revolution Medicines Inc (RVMD) a Stock to Watch After Losing -17.32% This Week?

Revolution Medicines Inc (RVMD) stock is lower by 17.32% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Revolution Medicines Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock is up 1.41% while the S&P 500 has fallen -0.36% as of 3:34 PM on Tuesday, Aug 2. RVMD has risen $0.28 from the previous closing price of $19.82 on volume of 601,997 shares. Over the past year the S&P 500 is lower by -6.46% while RVMD has fallen -31.49%. RVMD lost -$2.81 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Revolution Medicines Inc click here.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.